Arbutus Biopharma Corporation

Financials

Cash from operating activities -51.44 M-67.53 M-35.36 M-85.94 M-64.85 M-39.64 M -39.64 M Cash from investing activities -14.91 M-12.68 M-74.94 M50.77 M22.95 M15.58 M 15.58 M Cash from financing activities 86.75 M137.24 M31.81 M30.65 M52 M5.72 M 5.72 M Free cash flow -51.67 M-68.34 M-35.87 M-86.94 M-65.03 M-39.64 M -39.64 M

Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection. It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007.

ABUS

Financials

Arbutus Biopharma Corporation

Nouvelles

Le BPA de Arbutus Biopharma a dépassé les attentes de 0,02$, le CA a surpassé les prévisions

Moderna conclut un accord de 950 millions de dollars avec Arbutus et Genevant

Moderna reaches $950 million settlement with Arbutus and Genevant over patent litigation

Why Moderna’s $950M Patent Bill Is A Small Price For Pipeline Freedom (NASDAQ:MRNA)

Chardan réitère sa recommandation sur l’action Arbutus Biopharma après l’accord avec Moderna

Chardan reiterates Arbutus Biopharma stock rating on Moderna deal

MRNA Stock Gains on $2.25B Deal to Settle Patent Dispute With ROIV, ABUS

Le règlement de 950 millions de dollars de Moderna dissipe les incertitudes juridiques, faisant grimper l'action | Benzinga France

Moderna rises as up to $2.25 billion settlement for COVID vaccine patent dispute to remove overhang

Moderna shares jump as settlement removes major legal overhang

L’action Moderna bondit après un accord qui lève une incertitude juridique majeure

Stock Market Today: Dow, Nasdaq Higher; Bitcoin Surges On Trump News (Live Coverage)